Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: A systematic review

European Journal of Human Genetics

Volumn 15, Issue 6, 2007, Pages 619-627

  Gerhardus, Ansgar ^a,b   Schleberger, Henriette ^b   Schlegelberger, Brigitte ^b   Gadzicki, Dorothea ^b  

^a BIELEFELD UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EXTERNAL VALIDITY; FLUORESCENCE; GEL ELECTROPHORESIS; GENE MUTATION; GENE SEQUENCE; HUMAN; INTERNAL VALIDITY; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; STOP CODON;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC TECHNIQUES; HUMANS; MICRONUCLEUS TESTS; MUTATION; NUCLEIC ACID DENATURATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, RNA;

EID: 34249717959     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201806     Document Type: Review

References (39)

1. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
2. Miki Y, Swensen J, Shattuck-Eidens D et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
3. Wooster R, Bignell G, Lancaster J et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
4. Antoniou AC, Pharoah PDP, McMullan G et al: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 76-83.
5. Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185-187.
6. Meindl A, German Consortium for Hereditary Breast and Ovarian Cancer: Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002; 97: 472-480.
7. Sevilla C, Julian-Reynier C, Eisinger F et al: Impact of gene patents on the cost-effective delivery of care: The case of BRCA1 genetic testing. Int J Technol Assess Health Care 2003; 19: 287-300.
8. Cotton RGH, Edkins E, Forrest S: Mutation Detection. A Practical Approach. Oxford: University Press, 1998.
9. Hecker KH: Genetic Variance Detection. Technologies for Pharmacogenomics. DNA Press: Eagleville, PA, 2004.
10. Hecker KH: Genetic Variance Detection. Nuts and Bolts of DHPLC in Genomics. DNA Press: Eagleville, PA, 2004.
11. Gerhardus A, Schleberger H, Schlegelberger B, Schwartz FW (eds): BRCA - Erblicher Brust- und Eierstockkrebs. Springer: Beratung, Testverfahren, Kosten, Heidelberg, 2005.
12. Egger M, Smith GD, Altman DG: Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001.
13. Arnold N, Gross E, Schwarz-Boeger U et al: A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum Mutat 1999; 14: 333-339.
14. Eng C, Brody LC, Wagner TM et al: Interpreting epidemiological research: Blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet 2001; 38: 824-833.
15. Flynn KL, Adams EJ: Assessing Diagnostic Technologies. Technology Assessment Program Report No. 1. Boston: US Dept of Veterans Affairs, 1996.
16. American Society of Clinical Oncology (ASCO): Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 1996; 14: 1730-1736.
17. NICE. NICE Clinical Guideline 14: Familial Breast Cancer: The Classification and Care of Women at Risk of familial Breast Cancer in Primary, Secondary and Tertiary Care. London: National Institute for Clinical Excellence, 2004.
18. Noorani HZ, McGahan L: Predictive Genetic Testing for Breast and Prostate Cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1999.
19. Ho C, Banerjee S, Mensinkai S: Molecular Diagnosis for Hereditary Cancer Predisposing Syndromes: Genetic Testing and Clinical Impact. Technology Report No 41. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2003.
20. ITA: Prädiktive humangenetische Diagnostik bei hereditärem Mammaund Kolorektalkarzinom: Ein Assessment. Vienna: Institut für Technikfolgenabschätzung, 2002.
21. McGahan L, Kakuma R, Ho C et al: BRCA1 and BRCA2 Predictive Genetic Testing for Breast and Ovarian Cancers. A Systematic Review of Clinical Evidence [Technology report no 66]. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2006.
22. Rothfuss A, Schutz P, Bochum S et al: Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res 2000; 60: 390-394.
23. Jakubowska A, Gorski B, Byrski T et al: Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. Hum Mutat 2001; 18: 149-156.
24. Andrulis IL, Anton-Culver H, Beck J et al: Comparison of DNA-and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 2002; 20: 65-73.
25. Ganguly T, Dhulipala R, Godmilow L, Ganguly A: High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1- negative breast cancer families. Hum Genet 1998; 102: 549-556.
26. Casadei S, Cortesi L, Pensotti V et al: Detection of germline BRCA1 mutations by multiple-dye cleavase fragment length polymorphism (MD-CFLP) method. Br J Cancer 2001; 85: 845-849.
27. Kringen P, Egedal S, Pedersen JC et al: BRCA1 mutation screening using restriction endonuclease fingerprinting-single-strand conformation polymorphism in an automated capillary electrophoresis system. Electrophoresis 2002; 23: 4085-4091.
28. Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M: A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet 1999; 105: 72-78.
29. Sakayori M, Kawahara M, Shiraishi K et al: Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA1 and BRCA2 genes in familial breast cancer. J Hum Genet 2003; 48: 130-137.
30. Breslauer HJ, Frank R, Blöcker H, Marky LA: Predicting DNA duplex stability from the base sequence. Proc Natl Acad Sci USA 1986; 83: 3746-3750.
31. Panjkovich A, Melo F: Comparison of different melting temperature calculation methods for short DNA sequences. Bioinformatics 2005; 21: 711-722.
32. Lijmer JG, Mol BW, Heisterkamp S et al: Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999; 282: 1061-1066.
33. Lewis AG, Flanagan J, Marsh A et al: Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 2005; 7: R1005-1006.
34. Rashid MU, Jakubowska A, Justenhoven C et al: German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 2005; 41: 2896-2903.
35. Dagan E, Laitman Y, Levanon N et al: The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel. Fam Cancer 2006; 5: 389-395.
36. Hogervorst FB, Nederlof PM, Gille JJ et al: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003; 63: 1449-1453.
37. Gad S, Klinger M, Caux-Moncoutier V et al: Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families. J Med Genet 2002; 39 817-821.
38. Hartmann C, John A, Klaes R et al: Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat 2004; 24: 1-8.
39. Haverkamp A, Gerhardus A, Krauth C: Kosten der genetischen Beratung und der molekulargenetischen Diagnostik bel BRCA-Mutatione; in Gerhardus A, Schleberger H, Schlegelberger B, Schwartz FW (eds): BRCA - Erblicher Brust-und Eierstockkrebs. Beratung - Testverfahren - Kosten: Heidelberg, Springer, 2005, pp 140-171.